Market Overview

Bulletin from Extraordinary General Meeting of Diamyd Medical AB


Regulatory News:

The Extraordinary General Meeting of Diamyd Medical AB (publ)(STO:DIAMB)(Pink Sheets:DMYDY) held today decided in accordance with the Board's resolution, to approve the agreement to sell all shares in the subsidiary, Diamyd, Inc. to Periphagen Holdings, Inc.

About Diamyd Medical

Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company's development project within the area of diabetes consists of the protein GAD65 for the treatment and prevention of autoimmune diabetes. A Swedish researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can prevent type 1 diabetes in children who are at high risk of developing the disease. The Company's development projects for the treatment of chronic pain and neuropathy uses the patented NTDDS (Nerve Targeting Drug Delivery System) platform to administer therapeutic agents directly to the nervous system. The NTDDS platform is being divested.

Diamyd Medical also has holdings in the companies Protein Sciences Corporation (USA) and Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the Company's website:

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.

Diamyd Medical AB (publ)

Karlav├Ągen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: Reg. no: 556530-1420

This information was brought to you by Cision

Diamyd Medical AB
Peter Zerhouni, President and CEO
Phone: +46 8 661 00 26.

View Comments and Join the Discussion!